Microneedles as Transdermal Drug Delivery System for Enhancing Skin Disease Treatment
Acta Pharmaceutica Sinica B,
Год журнала:
2024,
Номер
14(12), С. 5161 - 5180
Опубликована: Авг. 23, 2024
Microneedles
(MNs)
serve
as
a
revolutionary
paradigm
in
transdermal
drug
delivery,
heralding
viable
resolution
to
the
formidable
barriers
presented
by
cutaneous
interface.
This
review
examines
MNs
an
advanced
approach
enhancing
dermatological
pathology
management.
It
explores
complex
dermis
structure
and
highlights
limitations
of
traditional
methods,
emphasizing
MNs'
advantage
bypassing
stratum
corneum
deliver
drugs
directly
subdermal
matrix.
The
discourse
outlines
diverse
typologies
MNs,
including
solid,
coated,
hollow,
hydrogel,
dissolvable
versions.
Each
type
is
characterized
its
unique
applications
benefits.
treatise
details
deployment
alleviation
cancers,
administration
inflammatory
dermatoses
such
psoriasis
atopic
dermatitis,
their
utility
wound
Additionally,
paper
contemplates
prospects
within
realm
aesthetic
dermatology
burgeoning
market
traction
cosmetic
MN
formulations.
summarizes
scientific
commercial
challenges
clinical
adoption
therapeutics,
dosage
calibration,
pharmacodynamics,
biocompatibility,
patient
compliance,
sterilization,
mass
production,
regulatory
oversight.
emphasizes
need
for
ongoing
research,
innovation,
harmonization
overcome
these
obstacles
fully
realize
potential
treating
skin
diseases
improving
welfare.
presents
comprehensive
overview
recent
accomplishments,
remaining
challenges,
future
microneedle-facilitated
therapy
afflictions.
Язык: Английский
Epidermal Mechanical Scratching-Induced ROS Exacerbates the Itch-Scratch Cycle via TRPA1 Activation on Mast Cells in Atopic Dermatitis
Journal of Investigative Dermatology,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Noncoding RNAs in Atopic Dermatitis: Insight Into Inflammation and Immune Regulation
Dermatologic Therapy,
Год журнала:
2025,
Номер
2025(1)
Опубликована: Янв. 1, 2025
Atopic
dermatitis
(AD)
is
a
chronic
inflammatory
skin
disorder
affecting
approximately
20%
of
children
and
10%
adults.
While
previous
studies
have
linked
AD
to
allergen
exposure,
disruption
the
barrier,
Type
2
immune
responses,
precise
pathophysiology
remains
elusive,
significantly
limiting
effectiveness
current
treatments.
Noncoding
RNAs
(ncRNAs),
diverse
group
transcripts
that
do
not
encode
proteins
account
for
at
least
98%
human
genome,
are
implicated
in
numerous
physiological
pathological
processes.
A
growing
body
evidence
underscores
pivotal
role
ncRNAs
pathogenesis
progression
AD.
This
review
offers
detailed
synthesis
latest
insights
into
involvement
AD,
as
well
their
potential
diagnostic
biomarkers
therapeutic
targets.
Язык: Английский
Prim-O-glucosylcimifugin mitigates atopic dermatitis by inhibiting Th2 differentiation through LCK phosphorylation modulation
Journal of Integrative Medicine,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
Язык: Английский
Stratum corneum pH and ceramides: key regulators and biomarkers of skin barrier function in atopic dermatitis
Journal of Dermatological Science,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 1, 2025
Язык: Английский
Advancements in artificial intelligence for atopic dermatitis: diagnosis, treatment, and patient management
Annals of Medicine,
Год журнала:
2025,
Номер
57(1)
Опубликована: Апрель 8, 2025
Atopic
dermatitis
(AD)
is
a
common
and
complex
skin
disease
that
significantly
affects
the
quality
of
life
patients.
The
latest
advances
in
artificial
intelligence
(AI)
technology
have
introduced
new
methods
for
diagnosing,
treating,
managing
AD.
AI
has
various
innovative
applications
diagnosis
treatment
atopic
dermatitis,
with
particular
emphasis
on
its
significant
benefits
medical
diagnosis,
monitoring,
patient
care.
algorithms,
especially
those
use
deep
learning
techniques,
demonstrate
strong
performance
recognizing
images
effectively
distinguishing
different
types
lesions,
including
AD
manifestations.
In
addition,
also
shown
promise
creating
personalized
plans,
simplifying
drug
development
processes,
clinical
trials.
Despite
challenges
data
privacy
model
transparency,
potential
advancing
care
enormous,
bringing
future
to
precision
medicine
improving
outcomes.
This
manuscript
provides
comprehensive
review
application
process
first
time,
aiming
play
key
role
advancement
health
further
enhance
Язык: Английский
Halting the Vicious Cycle of Atopic Dermatitis: Empowered by Scientific Understanding
Journal of Investigative Dermatology,
Год журнала:
2024,
Номер
144(5), С. 917 - 918
Опубликована: Апрель 19, 2024
The
progress
in
our
understanding
of
atopic
dermatitis
(AD)
(atopic
eczema)
the
last
10
years
has
been
remarkable.
Nearly
half
scientific
papers
ever
published
on
AD
have
written
years.
This
contribution
knowledge,
parallel
with
technological
and
pharmaceutical
progress,
transformed
ability
to
treat
some
most
severe
forms
AD.
Notably,
we
seen
advent
biologics
such
as
anti–IL-4
receptor
biologic
dupilumab
(Simpson
et
al,
2016),
2
anti–IL-13
agents
(tralokinumab
[Wollenberg
2021]
lebrikizumab
[Silverberg
2023]),
small-molecular
Jak
inhibitors
(the
Jak1
upadacitinib
[Guttman-Yassky
abrocitinib
[Simpson
2020]
Jak1/Jak2
inhibitor
baricitinib
[Zhou
2021]).
Язык: Английский
Revolutionizing Pediatric Dermatology: Dupilumab’s Impact on Atopic Dermatitis in Kids
Eiman Hamza Ahmed Elsayed,
Rabab Elsayed Ali Hassan Khater
American Journal of Life Science and Innovation,
Год журнала:
2024,
Номер
3(1), С. 61 - 68
Опубликована: Июнь 4, 2024
Eczema,
or
atopic
dermatitis,
is
a
common,
non-communicable,
immune-mediated,
inflammatory
skin
illness
mainly
affecting
children.
It
chronic
condition.
causes
mental
health
problems
like
anxiety,
sadness,
depression,
hyperactivity,
and
obesity.
the
first
ailment
fifteenth
non-fatal
disease.
The
purpose
of
present
research
study
was
to
evaluate
Safety
Effectiveness
biological
treatment
for
dermatitis
using
monoclonal
antibodies
against
non-biological
treatment,
including
antibiotics,
immunosuppressants,
demards,
histamine
antagonists
corticosteroids.
Patient
information
gathered
from
FDA-approved
clinical
trials.
comparative
analysis
found
that
Biological
therapies
Dupilumab,
Omalizumab,
Ustekinumab
improve
symptoms
disease
control
in
dermatitis.
Non-biological
treatments
may
not
be
as
effective.
Early
antibiotic
exposure
can
increase
infection
vulnerability.
Mild
eczema
infections
require
agents.
Topical
corticosteroids
combined
with
Dupilumab
effective
Studies
show
improves
quality
life,
making
it
better
option
than
placebo.
FDA
recommends
agents
over
immunosuppressants
paediatrics
improved
immune
results.
trials
showed
dupilumab
safe
children
moderate-to-severe
reducing
severity
improving
life
young
AD
patients.
Язык: Английский
Prurit et douleur cutanée au cours de la dermatite atopique
Annales de Dermatologie et de Vénéréologie - FMC,
Год журнала:
2024,
Номер
4(5), С. S27 - S34
Опубликована: Июнь 1, 2024
Updated insights into the molecular pathogenesis of canine atopic dermatitis
Veterinary Dermatology,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 25, 2024
Abstract
Atopic
dermatitis
(AD)
is
a
common
and
chronic
inflammatory
skin
disease
with
frequent
relapses.
The
genomics
revolution
has
greatly
contributed
revolutionised
our
knowledge
of
human
AD;
understanding
the
molecular
fingerprint
AD
associated
pathogenic
immune
pathways
led
to
preclinical
assessments
several
novel
treatments.
Initial
studies
using
microarray
analysis
analyse
transcriptome
(gene
expression)
changes
provided
relevant
insight
on
structural
occurring
at
time
acute
or
lesions,
after
immunomodulating
treatments
drugs
ciclosporin
dupilumab,
monoclonal
antibody
anti‐IL4
receptor.
revealed
that
characterised
by
activation
multiple
cytokine
(predominance
T
helper
cell
[Th]2
some
Th1,
Th17
Th22)
as
well
dysregulated
expression
barrier
components
in
skin.
There
are
reports
different
single
targets
(e.g.
interleukin
[IL]‐13,
CCL17
periostin)
spontaneous
canine
(cAD).
However,
significant
have
been
limited
study
analysing
lesions
dogs.
While
revealing
large
number
genes
differentially
expressed
cAD
skin,
small
sample
size
(n
=
13
dogs)
lack
key
epidermal
microarrays
inhibited
discussion
towards
specific
immunological
changes.
This
review
summarises
current
literature
regarding
mechanisms
cAD,
including
recent
data
RNA
sequencing,
compares
aspects
previously
published
from
AD.
Язык: Английский